Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.

Kato T, Nakai Y, Sato M, Takao T, Iwanishi T, Toyoda S, Osaki H, Tsujihata M, Okada K, Kakimoto K, Horitani H, Ono Y, Nishimura K, Takada S, Fujita K, Takayama H, Miyake O, Nakayama M, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Nonomura N.

Open source

DOI: 10.1038/s41598-025-27578-6
Published: 2025-12-12
Container: Sci Rep
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41598-025-27578-6,
  title = {Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.},
  author = {Kato T and  Nakai Y and  Sato M and  Takao T and  Iwanishi T and  Toyoda S and  Osaki H and  Tsujihata M and  Okada K and  Kakimoto K and  Horitani H and  Ono Y and  Nishimura K and  Takada S and  Fujita K and  Takayama H and  Miyake O and  Nakayama M and  Ishizuya Y and  Hayashi T and  Yamamoto Y and  Hatano K and  Kawashima A and  Nonomura N.},
  year = {2025},
  journal = {Sci Rep},
  doi = {10.1038/s41598-025-27578-6},
  url = {https://doi.org/10.1038/s41598-025-27578-6}
}

RIS

TY  - JOUR
TI  - Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.
AU  - Kato T
AU  -  Nakai Y
AU  -  Sato M
AU  -  Takao T
AU  -  Iwanishi T
AU  -  Toyoda S
AU  -  Osaki H
AU  -  Tsujihata M
AU  -  Okada K
AU  -  Kakimoto K
AU  -  Horitani H
AU  -  Ono Y
AU  -  Nishimura K
AU  -  Takada S
AU  -  Fujita K
AU  -  Takayama H
AU  -  Miyake O
AU  -  Nakayama M
AU  -  Ishizuya Y
AU  -  Hayashi T
AU  -  Yamamoto Y
AU  -  Hatano K
AU  -  Kawashima A
AU  -  Nonomura N.
PY  - 2025
JO  - Sci Rep
DO  - 10.1038/s41598-025-27578-6
UR  - https://doi.org/10.1038/s41598-025-27578-6
ER  -

APA

T, K., Y, N., M, S., T, T., T, I., S, T., H, O., M, T., K, O., K, K., H, H., Y, O., K, N., S, T., K, F., H, T., O, M., M, N., Y, I., T, H., Y, Y., K, H., A, K., & N., N. (2025). Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.. Sci Rep. https://doi.org/10.1038/s41598-025-27578-6

Source records

europe-pmc · retrieved 2026-09-27T06:12:18.077Z
doaj · retrieved 2026-09-27T06:12:18.091Z